Actuate Therapeutics (ACTU) said Friday that its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer demonstrated the use of machine learning and statistical models to predict overall survival based on pre-dose plasma biomarkers.
The analysis identified seven biomarkers as "uniquely significant" predictors of favorable survival in the elraglusib-treated cohort, the biopharmaceutical company said.
The biomarker CXCL2 had an inverse survival trend compared to the gemcitabine/nab-paclitaxel control arm, "highlighting the potential of elraglusib to favorably affect the immune microenvironment," Actuate said.
The company said it plans to test the identified biomarkers prospectively in future trials.
Shares were 5.8% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。